Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab

Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab

Copyright 2020, SLACK Incorporated.

Détails bibliographiques
Publié dans:Ophthalmic surgery, lasers & imaging retina. - 2013. - 51(2020), 3 vom: 01. März, Seite 145-151
Auteur principal: Ebrahimiadib, Nazanin (Auteur)
Autres auteurs: Lashay, Alireza, Riazi-Esfahani, Hamid, Jamali, Sepideh, Khodabandeh, Alireza, Zarei, Mohammad, Roohipoor, Ramak, Khojasteh, Hassan, Bazvand, Fatemeh, Ojani, Mina, Shahabinejad, Mojtaba, Yaseri, Mehdi, Modjtahedi, Bobeck S, Davoudi, Samaneh, Riazi-Esfahani, Mohammad
Format: Article en ligne
Langue:English
Publié: 2020
Accès à la collection:Ophthalmic surgery, lasers & imaging retina
Sujets:Journal Article Angiogenesis Inhibitors Recombinant Fusion Proteins aflibercept 15C2VL427D Bevacizumab 2S9ZZM9Q9V Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1
Description
Résumé:Copyright 2020, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: To evaluate the efficacy of intravitreal ziv-aflibercept (IVZ) in patients with diabetic macular edema (DME) resistant to intravitreal bevacizumab (IVB)
PATIENTS AND METHODS: This prospective study was conducted in patients with persistent DME. Patients were switched to IVZ no longer than 6 weeks after the last three consecutive monthly IVB treatments and monitored over a course of 12 weeks. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and macular volume on optical coherence tomography were compared
RESULTS: A total of 59 eyes (38 patients) were included. Mean BCVA improved from 0.84 to 0.71 logMAR (P = .001) after first IVZ treatment and remained significant. In a subgroup analysis, this significance was observed only in the group with baseline visual acuity of less than 20/50. Mean CMT decreased from 479 μm to 364 μm (P = .004) after the first IVZ injections and remained significant
CONCLUSION: IVZ may be best reserved for patients with persistent DME after initial failure with bevacizumab, with less likelihood for anatomic or functional improvement in those with mild persistent DME. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:145-151.]
Description:Date Completed 14.04.2021
Date Revised 14.04.2021
published: Print
Citation Status MEDLINE
ISSN:2325-8179
DOI:10.3928/23258160-20200228-03